CEO Martin Babler was paid $5,948,289 in fiscal year 2025, ↓ down 44.2% from fiscal year 2024 (SEC filing 0001104659-26-063223 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$5,948,289 ↓ Martin Babler total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read Alumis's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper ALMS reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ALMS's next annual pay disclosure, estimated April 19, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Martin Babler | $680,830 | $0 | $0 | $4,743,220 | $524,239 | $0 | $0 | $5,948,289 |
| President, Chief Executive Officer, and Chairman of the Board | ||||||||
| David Goldstein | 526,401 | 0 | 0 | 1,187,353 | 294,785 | 0 | 0 | 2,008,539 |
| Chief Scientific Officer | ||||||||
| Jörn Drappa | 523,755 | 0 | 0 | 1,161,607 | 293,303 | 0 | 0 | 1,978,665 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Martin Babler | $5,948,289 | $10,661,219 | — | ↓ −4,712,930 |
| David Goldstein | 2,008,539 | 3,244,462 | — | ↓ −1,235,923 |
| Jörn Drappa | 1,978,665 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses ALMS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALMS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alan B. Colowick, M.D., M.P.H | Independent Director | — |
| James B. Tananbaum, M.D | Independent Director | — |
| Julian Baker | Former director (through FY2024) | — |
| Patrick Machado, J.D | Independent Director | $226,307 |
| Richard Gaster, M.D | Former director (through FY2024) | — |
| Sapna Srivastava, Ph.D | Independent Director | $225,730 |
| Srinivas Akkaraju, Ph.D | Independent Director | — |
| Zhengbin Yao, Ph.D | Independent Director | — |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jörn Drappa | Option | 28,521 | 8.84 | — |
| Martin Babler | Option | 2,229 | 8.84 | — |
| David Goldstein | Option | 59,715 | 8.84 | — |
| Jörn Drappa | Option | 30,682 | 8.84 | — |
| Jörn Drappa | RSU | 25,450 | — | 248,392 |
| Martin Babler | Option | 93,182 | 8.84 | — |
| Martin Babler | Option | 49,055 | 8.84 | — |
| David Goldstein | Option | 892 | 8.84 | — |
| Martin Babler | Option | 186,609 | 8.84 | — |
| Martin Babler | Option | 13,369 | 16 | — |
| Jörn Drappa | Option | 101,850 | 3.95 | — |
| Jörn Drappa | Option | 3,342 | 16 | — |
| Martin Babler | Option | 135,681 | 8.84 | — |
| David Goldstein | RSU | 27,000 | — | 263,520 |
| Jörn Drappa | Option | 8,549 | 8.84 | — |
| Martin Babler | Option | 153,742 | 13.32 | — |
| Jörn Drappa | Option | 4,546 | 8.84 | — |
| Jörn Drappa | Option | 180,000 | 5.06 | — |
| Martin Babler | Option | 523,000 | 5.06 | — |
| David Goldstein | Option | 14,045 | 8.84 | — |
| Martin Babler | Option | 662,000 | 3.95 | — |
| Martin Babler | Option | 150,000 | 3.95 | — |
| David Goldstein | Option | 5,303 | 8.84 | — |
| Jörn Drappa | Option | 38,218 | 8.84 | — |
| David Goldstein | Option | 33,422 | 13.32 | — |
| David Goldstein | Option | 180,000 | 5.06 | — |
| David Goldstein | Option | 107,950 | 3.95 | — |
| Jörn Drappa | Option | 40,107 | 13.32 | — |
The Board considers market compensation for comparable positions, historical compensation levels, individual performance against expectations, and the desire to motivate employees to achieve short- and long-term results in the best interests of stockholders. Equity awards are used as the primary vehicle for long-term incentives to align executive interests with stockholders and create an ownership culture.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick Machado, J.DIndependent · Audit (Chair) · Nominating and Corporate Governance | $65,000 | — | $161,307 | — | — | $226,307 |
| Sapna Srivastava, Ph.DIndependent · Lead Independent Director · Nominating and Corporate Governance | 64,423 | — | 161,307 | — | — | 225,730 |
| Srinivas Akkaraju, M.D., Ph.DIndependent · Audit · Science and Technology | 52,651 | — | 161,307 | — | — | 213,958 |
| Zhengbin (Bing) Yao, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology | 51,360 | — | 161,307 | — | — | 212,667 |
| Lynn Tetrault, J.DIndependent · Compensation | 28,832 | — | 161,307 | — | — | 190,139 |
| James B. Tananbaum, M.DIndependent · Compensation · Science and Technology | 0 | — | 0 | — | — | 0 |
| Martin BablerEmployee director · Board Chair | — | — | — | — | — | 0 |
| Alan B. Colowick, M.D., M.P.HIndependent · Audit · Compensation · Science and Technology | 0 | — | 0 | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $262,266 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $262,266 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Alumis | 2025 | Martin Babler | $680,830 | $0 | $4,743,220 | $524,239 | $5,948,289 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Martin Babler | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Summary Compensation Table”. As printed: 5,948,289. View filing ↗ |
| 2 | Section 01, David Goldstein | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Summary Compensation Table”. As printed: 2,008,539. View filing ↗ |
| 3 | Section 01, Jörn Drappa | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Summary Compensation Table”. As printed: 1,978,665. View filing ↗ |
| 4 | Section 08, Patrick Machado, J.D | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 226,307. View filing ↗ |
| 5 | Section 08, Sapna Srivastava, Ph.D | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 225,730. View filing ↗ |
| 6 | Section 08, Srinivas Akkaraju, M.D., Ph.D | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 213,958. View filing ↗ |
| 7 | Section 08, Zhengbin (Bing) Yao, Ph.D | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 212,667. View filing ↗ |
| 8 | Section 08, Lynn Tetrault, J.D | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 190,139. View filing ↗ |
| 9 | Section 08, James B. Tananbaum, M.D | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 10 | Section 08, Martin Babler | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 11 | Section 08, Alan B. Colowick, M.D., M.P.H | DEF 14A | 2026-05-18 | 0001104659-26-063223 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer. |
| 13 | Section 09b board cost (computed) | Computed | — | — | Cash 262,266 + equity 0 + all other 0 = 262,266, summed across the director compensation table rows. |
| 14 | Alumis (subject), Section 10b CEO total | DEF 14A | 2026-05-18 | 0001104659-26-063223 | CEO total compensation as printed in Alumis's own proxy. As printed: 5,948,289. View filing ↗ |